In the wake of the increase in Current Liabilities in the first quarter 2024, Quick Ratio fell to 0.26 a new company low.

Within Biotechnology & Pharmaceuticals industry 161 other companies have achieved higher Quick Ratio than Gamida Cell Ltd in first quarter 2024. While Quick Ratio total ranking in the first quarter 2024 has deteriorated compared to the prior quarter from 929 to 3611.

Explain Quick Ratio?
How much Cash & cash equivalents GMDA�s has?
What are GMDA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GMDA Quick Ratio	(Mar 31 2024) Q1	(Dec 31 2023) Q4	(Sep 30 2023) Q3	(Jun 30 2023) Q2	(Mar 31 2023) Q1
Y / Y Current Liabilities Change	239.85 %	-14.26 %	78.42 %	139.41 %	35.84 %
Y / Y Cash & cash equivalent Change	-73.51 %	-75.99 %	4.82 %	-20.18 %	-29.16 %
Quick Ratio MRQ	0.26	2.3	2.82	1.96	3.29
GMDA's Total Ranking	# 3611	# 929	# 994	# 1162	#
Seq. Current Liabilities Change	376.61 %	-50.95 %	-20.25 %	82.29 %	20.24 %
Seq. Cash & cash equivalent Change	-46.78 %	-60.09 %	14.78 %	8.67 %	-51.77 %

Quick Ratio first quarter 2024 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 162
Healthcare Sector	# 934
Overall Market	# 3611

Quick Ratio Statistics
High	Average	Low
153.55	21.84	0.26
(Sep 30 2021)		(Mar 31 2024)

Financial Statements
Gamida Cell Ltd 's Current Liabilities	$ 97 Millions	Visit GMDA's Balance sheet
Gamida Cell Ltd 's Cash & cash equivalent	$ 25 Millions	Visit GMDA's Balance sheet
Source of GMDA's Sales		Visit GMDA's Sales by Geography

Cumulative Gamida Cell Ltd 's Quick Ratio

GMDA's Quick Ratio for the trailling 12 Months

GMDA Quick Ratio	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months	(Mar 31 2023) 12 Months
Y / Y Current Liabilities TTM Growth	116.8 %	58.7 %	67.8 %	98.81 %	120.78 %
Y / Y Cash & cash equivalent TTM Growth	-44.94 %	-36.52 %	-2.4 %	2.64 %	14.2 %
Quick Ratio TTM	1.38	2.53	3.48	3.94	5.43
Total Ranking TTM	# 3629	# 755	# 867	# 3710	#
Seq. Current Liabilities TTM Growth	48.07 %	-2.32 %	14.3 %	31.15 %	8.39 %
Seq. Cash & cash equivalent TTM Growth	-19.18 %	-29.14 %	1.07 %	-4.89 %	-6.82 %

Quick ratio ranking by company, industry and sector >> Back to GMDA Financial Strength Comparisons >> Go to Compare GMDA Quick Ratio to its Competitors

News about Gamida Cell Ltd Quick Ratio

Gamida Cell Announces Restructuring Plan with Backing from Highbridge Capital Management

Gamida Cell Secures Funding for Allogeneic Stem Cell Transplant Commercialization
In a recent announcement, Gamida Cell Ltd disclosed plans to receive a significant injection of capital from Highbridge Capital Management to support the commercialization of their allogeneic stem cell transplant, Omisirge. This move comes as the company s cash and cash equivalents grew by 16.79% in the third quarter of 2023, while current liabilities decreased, resulting in an improved quick ratio of 3.06.
On a trailing twelve-month basis, Gamida Cell s cash and cash equivalents increased by 3.03% year on year in the third quarter of 2023, leading to a rise in their trailing twelve-month quick ratio to 2.58. Despite this improvement, the quick ratio remained below Gamida Cell s 12-month average.

On the trailing twelve months basis Due to in Current Liabilities in the Q1 2024 to $96.61 millions, cumulative Quick Ratio decreased to 1.38 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 154 other companies have achieved higher Quick Ratio than Gamida Cell Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2023 from 755 to 3629.

Explain Quick Ratio?
How much Cash & cash equivalents GMDA�s has?
What are GMDA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 155
Healthcare Sector	# 987
Within the Market	# 3629

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.1	2.43	1.19
(Sep 30 2022)		(Mar 31 2024)

Companies with similar Quick Ratio in the quarter ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Mar 31 2024 MRQ Cash & cash equivalent	Mar 31 2024 MRQ Current Liabilities
Vaxart Inc	0.70	$ 9.929 Millions	$ 14.117 Millions
Novavax inc	0.60	$ 480.586 Millions	$ 804.382 Millions
Windtree Therapeutics Inc	0.56	$ 2.547 Millions	$ 4.539 Millions
Mink Therapeutics Inc	0.52	$ 5.817 Millions	$ 11.108 Millions
Cyclo Therapeutics Inc	0.51	$ 2.995 Millions	$ 5.889 Millions
Dbv Technologies S a	0.51	$ 15.725 Millions	$ 31.066 Millions
Protalix Biotherapeutics inc	0.50	$ 27.209 Millions	$ 54.828 Millions
Amgen Inc	0.49	$ 9,708.000 Millions	$ 19,714.000 Millions
Coherus Oncology inc	0.48	$ 259.775 Millions	$ 538.303 Millions
Cel sci Corporation	0.46	$ 2.319 Millions	$ 5.087 Millions
Cidara Therapeutics Inc	0.44	$ 29.018 Millions	$ 65.425 Millions
Mesoblast Limited	0.43	$ 62.960 Millions	$ 145.521 Millions
Aptose Biosciences Inc	0.42	$ 4.881 Millions	$ 11.740 Millions
Elutia Inc	0.40	$ 12.551 Millions	$ 31.260 Millions
Armata Pharmaceuticals Inc	0.34	$ 37.860 Millions	$ 110.045 Millions
Champions Oncology Inc	0.32	$ 2.618 Millions	$ 8.110 Millions
Atara Biotherapeutics Inc	0.26	$ 46.239 Millions	$ 180.083 Millions
Gamida Cell Ltd	0.26	$ 24.776 Millions	$ 96.613 Millions
Genetic Technologies Limited	0.24	$ 0.681 Millions	$ 2.801 Millions
Biocardia Inc	0.23	$ 0.949 Millions	$ 4.071 Millions
Tc Biopharm holdings Plc	0.23	$ 1.522 Millions	$ 6.759 Millions
Agenus Inc	0.21	$ 52.856 Millions	$ 256.002 Millions
Zeo Scientifix Inc	0.21	$ 0.746 Millions	$ 3.621 Millions
Kiromic Biopharma Inc	0.19	$ 3.676 Millions	$ 19.093 Millions
Xtant Medical Holdings Inc	0.17	$ 4.547 Millions	$ 27.523 Millions
Tevogen Bio Holdings Inc	0.15	$ 1.318 Millions	$ 8.678 Millions
Brainstorm Cell Therapeutics inc	0.11	$ 0.779 Millions	$ 6.831 Millions
Calidi Biotherapeutics Inc	0.08	$ 1.143 Millions	$ 14.953 Millions

Date modified: 2026-06-23T19:22:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.